Eli Lilly lost the momentum it had during the first half of the year. However, the company still has plenty of ...
LLY's recent sell-off presents a buying opportunity for savvy investors, with strong growth potential in the GLP-1 market ...
In this piece, we will look at where Eli Lilly and Company (NYSE:LLY) ranks on the list. With the 2024 US Presidential Election having come to a close, Wall Street can now focus on the future ...
Eli Lilly now ranks as the largest drugmaker in the world based ... Much of Lilly's recent dismal stock performance ...
The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...
Eli Lilly and Company (NYSE: LLY) announced today that it has elected Jon Moeller as a new member of its board of directors ...
Earlier on Wednesday, Laekna, “a global biotech company focused on novel drug development for metabolic and cancer diseases,” accoding to its ...
The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...